TransCode Therapeutics, Inc.

NASDAQ (USD): TransCode Therapeutics, Inc. (RNAZ)

Last Price


Today's Change

-0.026 (3.58%)

Day's Change

0.67 - 0.72

Trading Volume



Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare


CEO:  Mr. Thomas A. Fitzgerald M.B.A. Mr. Thomas A. Fitzgerald M.B.A.

Full Time Employees:  19 19

IPO Date:  2021-07-08 2021-07-08

CIK:  0001829635 0001829635

ISIN:  US89357L3033 US89357L3033

CUSIP:  89357L105 89357L105

Beta:  -0.49 -0.49

Last Dividend:  0.00 0.00

Dcf Diff:  -3.85 -3.85

Dcf:  7.66 7.66


TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.


6 Liberty Square,
Boston, MA 02109, US


Be the first to like this. Showing 0 of 0 comments

Post a Comment